ArticleFrontiers in cardiovascular medicine2025
Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic heart failure (CHF) is a complex cardiovascular disease caused by different pathological mechanisms. Modern medicine has made advancements in CHF treatment; however, there are still many challenges. Ershen Zhenwu Decoction (ESZWD) is a Xin'an medicine that has been clinically applied for years and had good efficacy against CHF; however, its underlying mechanisms remain undetermined. Therefore, this study aims to investigate the primary molecular mechanisms of ESZWD in CHF treatment and elucidate its multi-target and multi-level mode of action. Objective: The aim of this study was to investigate the main molecular mechanisms of ESZWD for the treatment of CHF and to elucidate its multi-target and multi-level mode of action. Methods: This study employed a network pharmacology approach to analyze the main ESZWD components and core targets. Furthermore, primary CHF targets were predicted to develop a protein-protein interaction (PPI) network and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Moreover, molecular docking was carried out to validate the binding between active ingredients and key targets. For Results: Network pharmacology identified 437 targets for 34 major ESZWD components. Of these, 216 drug-disease intersection targets were identified. The PPI network analysis identified the following core targets: STAT3, HSP90AA1, MAPK8, NFKB1, HIF1A, MMP9, PTGS2, BCL2L1, TLR4, and ESR1. GO analysis revealed that these targets were associated with exogenous stimuli responses, phosphorylation regulation, inflammatory response, and protein tyrosine kinase activity. Furthermore, KEGG analysis showed that ESZWD predominantly impacts cancer, inflammatory response, and apoptosis pathways, with c-Jun N-terminal kinase/mitogen-activated protein kinase (JNK/MAPK)-regulated apoptosis being a key pathway. Conclusion: Our study shows that paeoniflorin, acetylaconitine, and cryptotanshinone bind to key proteins in the JNK/MAPK apoptosis pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.